Funding will support recruitment, commercial partnerships, and further development of Semarion's SemaCyte cell assaying platform, which turns adherent cells into liquid reagents to enable novel
Market bubbles – and subsequent crashes – are rarer than many people think, but all are driven by the same thing, says Merryn Somerset Webb: investors’ belief in something that always turns out to be impossible.